Selected research
Industry Growth & Trends
Global Next-Generation Tumor Genetic Testing Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Next-Generation Tumor Genetic Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Next-Generation Tumor Genetic Testing market include Devyser, Agendia, Illumina, Personal Genome Diagnostics, Veracyte, Pacific Biosciences of California, Qiagen, Agilent Technologies and Natera, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Next-Generation Tumor Genetic Testing market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Next-Generation Tumor Genetic Testing market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Next-Generation Tumor Genetic Testing market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Next-Generation Tumor Genetic Testing.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Next-Generation Tumor Genetic Testing market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Next-Generation Tumor Genetic Testing Market by Company
Devyser
Agendia
Illumina
Personal Genome Diagnostics
Veracyte
Pacific Biosciences of California
Qiagen
Agilent Technologies
Natera
Bio Rad Laboratories
Myriad Genetics
Next-Generation Tumor Genetic Testing Segment by Type
Fluorescence In Situ Hybridization
Polymerase Chain Reaction
Microarray Technology
Serum Proteomics
Nucleic Acid Sequencing
Next-Generation Tumor Genetic Testing Segment by Application
Hospitals
Speciality Clinics
Research Institutes
Diagnostics Laboratories
Biopharmaceutical Companies
Next-Generation Tumor Genetic Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Next-Generation Tumor Genetic Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Next-Generation Tumor Genetic Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Next-Generation Tumor Genetic Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Next-Generation Tumor Genetic Testing companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Fluorescence In Situ Hybridization
- Polymerase Chain Reaction
- Microarray Technology
- Serum Proteomics
- Nucleic Acid Sequencing
Applications
- Hospitals
- Speciality Clinics
- Research Institutes
- Diagnostics Laboratories
- Biopharmaceutical Companies
Companies covered
- Devyser
- Agendia
- Illumina
- Personal Genome Diagnostics
- Veracyte
- Pacific Biosciences of California
- Qiagen
- Agilent Technologies
- Natera
- Bio Rad Laboratories
- Myriad Genetics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Next-Generation Tumor Genetic Testing Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Next-Generation Tumor Genetic Testing Market Size by Region (2021-2032)
- 1.4.1 Global Next-Generation Tumor Genetic Testing Market Size by Region (2021-2026)
- 1.4.2 Global Next-Generation Tumor Genetic Testing Market Size by Region (2027-2032)
- 1.5 Key Regions Next-Generation Tumor Genetic Testing Market Size (2021-2032)
- 1.5.1 North America Next-Generation Tumor Genetic Testing Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Next-Generation Tumor Genetic Testing Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size Growth Rate (2021-2032)
- 1.5.4 South America Next-Generation Tumor Genetic Testing Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size Growth Rate (2021-2032)
2 Next-Generation Tumor Genetic Testing Market by Type
- 2.1 Type Introduction
- 2.1.1 Fluorescence In Situ Hybridization
- 2.1.2 Polymerase Chain Reaction
- 2.1.3 Microarray Technology
- 2.1.4 Serum Proteomics
- 2.1.5 Nucleic Acid Sequencing
- 2.2 Global Next-Generation Tumor Genetic Testing Market Size by Type
- 2.2.1 Global Next-Generation Tumor Genetic Testing Market Size Overview by Type (2021-2032)
- 2.2.2 Global Next-Generation Tumor Genetic Testing Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Next-Generation Tumor Genetic Testing Market Size Forecasted by Type (2027-2032)
- 2.3 Global Next-Generation Tumor Genetic Testing Market Size by Regions
- 2.3.1 North America Next-Generation Tumor Genetic Testing Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Next-Generation Tumor Genetic Testing Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Next-Generation Tumor Genetic Testing Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Next-Generation Tumor Genetic Testing Market Size Breakdown by Type (2021-2026)
3 Next-Generation Tumor Genetic Testing Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospitals
- 3.1.2 Speciality Clinics
- 3.1.3 Research Institutes
- 3.1.4 Diagnostics Laboratories
- 3.1.5 Biopharmaceutical Companies
- 3.2 Global Next-Generation Tumor Genetic Testing Market Size by Application
- 3.2.1 Global Next-Generation Tumor Genetic Testing Market Size Overview by Application (2021-2032)
- 3.2.2 Global Next-Generation Tumor Genetic Testing Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Next-Generation Tumor Genetic Testing Market Size Forecasted by Application (2027-2032)
- 3.3 Global Next-Generation Tumor Genetic Testing Market Size by Regions
- 3.3.1 North America Next-Generation Tumor Genetic Testing Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Next-Generation Tumor Genetic Testing Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Next-Generation Tumor Genetic Testing Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Next-Generation Tumor Genetic Testing Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Next-Generation Tumor Genetic Testing Industry Trends
- 4.2 Next-Generation Tumor Genetic Testing Industry Drivers
- 4.3 Next-Generation Tumor Genetic Testing Industry Opportunities and Challenges
- 4.4 Next-Generation Tumor Genetic Testing Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Next-Generation Tumor Genetic Testing Revenue (2021-2026)
- 5.2 Global Next-Generation Tumor Genetic Testing Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Next-Generation Tumor Genetic Testing Key Company Headquarters & Area Served
- 5.4 Global Next-Generation Tumor Genetic Testing Company, Product Type & Application
- 5.5 Global Next-Generation Tumor Genetic Testing Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Next-Generation Tumor Genetic Testing Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Next-Generation Tumor Genetic Testing Players Market Share by Revenue in 2025
- 5.6.3 2025 Next-Generation Tumor Genetic Testing Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Devyser
- 6.1.1 Devyser Company Information
- 6.1.2 Devyser Business Overview
- 6.1.3 Devyser Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Devyser Next-Generation Tumor Genetic Testing Product Portfolio
- 6.1.5 Devyser Recent Developments
- 6.2 Agendia
- 6.2.1 Agendia Company Information
- 6.2.2 Agendia Business Overview
- 6.2.3 Agendia Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Agendia Next-Generation Tumor Genetic Testing Product Portfolio
- 6.2.5 Agendia Recent Developments
- 6.3 Illumina
- 6.3.1 Illumina Company Information
- 6.3.2 Illumina Business Overview
- 6.3.3 Illumina Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Illumina Next-Generation Tumor Genetic Testing Product Portfolio
- 6.3.5 Illumina Recent Developments
- 6.4 Personal Genome Diagnostics
- 6.4.1 Personal Genome Diagnostics Company Information
- 6.4.2 Personal Genome Diagnostics Business Overview
- 6.4.3 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Product Portfolio
- 6.4.5 Personal Genome Diagnostics Recent Developments
- 6.5 Veracyte
- 6.5.1 Veracyte Company Information
- 6.5.2 Veracyte Business Overview
- 6.5.3 Veracyte Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Veracyte Next-Generation Tumor Genetic Testing Product Portfolio
- 6.5.5 Veracyte Recent Developments
- 6.6 Pacific Biosciences of California
- 6.6.1 Pacific Biosciences of California Company Information
- 6.6.2 Pacific Biosciences of California Business Overview
- 6.6.3 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Product Portfolio
- 6.6.5 Pacific Biosciences of California Recent Developments
- 6.7 Qiagen
- 6.7.1 Qiagen Company Information
- 6.7.2 Qiagen Business Overview
- 6.7.3 Qiagen Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Qiagen Next-Generation Tumor Genetic Testing Product Portfolio
- 6.7.5 Qiagen Recent Developments
- 6.8 Agilent Technologies
- 6.8.1 Agilent Technologies Company Information
- 6.8.2 Agilent Technologies Business Overview
- 6.8.3 Agilent Technologies Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Agilent Technologies Next-Generation Tumor Genetic Testing Product Portfolio
- 6.8.5 Agilent Technologies Recent Developments
- 6.9 Natera
- 6.9.1 Natera Company Information
- 6.9.2 Natera Business Overview
- 6.9.3 Natera Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Natera Next-Generation Tumor Genetic Testing Product Portfolio
- 6.9.5 Natera Recent Developments
- 6.10 Bio Rad Laboratories
- 6.10.1 Bio Rad Laboratories Company Information
- 6.10.2 Bio Rad Laboratories Business Overview
- 6.10.3 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Product Portfolio
- 6.10.5 Bio Rad Laboratories Recent Developments
- 6.11 Myriad Genetics
- 6.11.1 Myriad Genetics Company Information
- 6.11.2 Myriad Genetics Business Overview
- 6.11.3 Myriad Genetics Next-Generation Tumor Genetic Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Myriad Genetics Next-Generation Tumor Genetic Testing Product Portfolio
- 6.11.5 Myriad Genetics Recent Developments
7 North America
- 7.1 North America Next-Generation Tumor Genetic Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 7.3 North America Next-Generation Tumor Genetic Testing Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Next-Generation Tumor Genetic Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 8.3 Europe Next-Generation Tumor Genetic Testing Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Next-Generation Tumor Genetic Testing Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Next-Generation Tumor Genetic Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 10.3 South America Next-Generation Tumor Genetic Testing Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Next-Generation Tumor Genetic Testing Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst